Skip to product information
1 of 1

MULTI SCIENCES

Human Chitinase 3-like 1/CHI3L1 Antibody ELISA Kit

Human Chitinase 3-like 1/CHI3L1 Antibody ELISA Kit

SKU:EK1164

Regular price Send Inquiry
Regular price Sale price Send Inquiry
Sale Sold out
View full details

Product Details

Human Chitinase 3-like 1/CHI3L1 Antibody ELISA Kit

Brand

MultiSciences

Cat Num

70-EK1164

Product Name

Human Chitinase 3-like 1/CHI3L1 ELISA Kit

Customs Name

Human Chitinase 3-like 1/CHI3L1 ELISA Kit

Application

ELISA

Reactivity

Human

Assay Type

Sandwich ELISA

Suitable Sample Type

serum, plasma, cell culture supernates

Format

96-well strip plate

Storage

4℃ (unopened)standard stored at -20℃, others stored at 4℃ (opened)

Shipping Condition

4℃

Sample Volume

50 μl

Sensitivity

1.10 pg/ml

Standard Curve Range

15.63 - 1000 pg/ml

Spike Recovery Range

-

Mean Spike Recovery

-

CV of Intra plate

1.8 % - 4.7 %

CV of Inter plate

2.1 % - 3.2 %

Components

96-well polystyrene microplate coated with a monoclonal antibody against CHI3L1
Human CHI3L1 Standard, lyophilized
CHI3L1 Detect Antibody
Streptavidin-HRP
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
Washing Buffer (20×)
Plate Covers

Describtion

This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human CHI3L1. The Human Chitinase-3-like 1/CHI3L1 ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Chitinase-3-like 1 (CHI3L1) is secreted by various cell-types including macrophages, chondrocytes, and some types of cancer cells. The exact physiological role of CHI3L1 is not known, but it has been implicated in development, inflammatory disease (such as asthma, and cancer progression).
CHI3L1 is a Th2 promoting cytokine that is present at high levels in the tumor micro-environment and in the serum of cancer patients. Elevated levels of CHI3L1 correlate strongly with stage and outcome of various types of cancer, which establish CHI3L1 as a biomarker of disease severity. Targeting CHI3L1 with neutralizing antibodies has been proven effective as a treatment in animal models of glioblastoma multiforme. CHI3L1 is able to promote angiogenesis through VEGFdependent and independent pathways. CHI3L1 also enhances tumor survival in response to γ-irradiation.